[A25-153] Lisocabtagene maraleucel (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V
Last updated 16.03.2026
Project no.:
A25-153
Commission:
Commission awarded on 15.12.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-153
| Project no. | Title | Status |
|---|---|---|
| A25-47 | Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-98 | Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48 | Commission completed |
| A22-90 | Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) – Benefit assessment according to §35a Social Code Book V | Commission completed |